Q2 2014 13F Holders as of 30 Jun 2014
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
74.2M
-
Number of holders
-
60
-
Total 13F shares, excl. options
-
22.5M
-
Shares change
-
-4.54M
-
Total reported value, excl. options
-
$23.4M
-
Value change
-
-$4.7M
-
Number of buys
-
24
-
Number of sells
-
-41
-
Price
-
$1.04
Significant Holders of ENZON PHARMACEUTICALS, INC. - Common Stock, par value $0.01 per share (ENZN) as of Q2 2014
80 filings reported holding ENZN - ENZON PHARMACEUTICALS, INC. - Common Stock, par value $0.01 per share as of Q2 2014.
ENZON PHARMACEUTICALS, INC. - Common Stock, par value $0.01 per share (ENZN) has 60 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 22.5M shares
of 74.2M outstanding shares and own 30.31% of the company stock.
Largest 10 shareholders include ICAHN CARL C (5.9M shares), BlackRock Institutional Trust Company, N.A. (3.14M shares), VANGUARD GROUP INC (1.25M shares), DIMENSIONAL FUND ADVISORS LP (1.15M shares), RENAISSANCE TECHNOLOGIES LLC (1.12M shares), BRANDES INVESTMENT PARTNERS, LP (1.04M shares), BlackRock Advisors LLC (818K shares), PRICE MICHAEL F (748K shares), UBS AG (715K shares), and GOLDMAN SACHS GROUP INC (434K shares).
This table shows the top 60 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.